TY - JOUR
T1 - The Economics of Malaria Vaccine Development
AU - Plebanski, Magdalena
AU - Flanagan, Katie L.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).
AB - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).
UR - http://www.scopus.com/inward/record.url?scp=85011416633&partnerID=8YFLogxK
U2 - 10.1016/j.pt.2017.01.006
DO - 10.1016/j.pt.2017.01.006
M3 - Comment / Debate
AN - SCOPUS:85011416633
VL - 33
SP - 154
EP - 156
JO - Trends in Parasitology
JF - Trends in Parasitology
SN - 1471-4922
IS - 3
ER -
